It has long been recognized that herpes simplex virus thymidine kinase (TK) is able to phosphorylate certain nucleoside analogues to their monophosphate forms in infected cells, whereas host cells do this poorly [1,2]. This effect has led to the identification of selective antiviral compounds, some of which have been developed as drugs, including idoxuridine, acyclovir, ganciclovir and penciclovir [3]. The herpes simplex virus possesses a type I TK that has a broader substrate specificity than the host cell type II TK and orthopoxvirus type II TK [4,5]. Because of the narrow substrate specificity of poxvirus TK, there have been few discoveries of compounds that are selectively phosphorylated by poxvirus TK. Prichard and colleagues [6,7] presented evidence that the antiviral potencies of 5-bromo-2′-deoxyuridine (BrdU), 5-iodo-2′-deoxyuridine (IdU) and N-methanocarbathymidine [(N)-MCT] were greater against TK-containing (TK + ) cowpox virus than against TK-deficient (TK -) cowpox virus. This suggested that the compounds were activated by cowpox virus TK and gave an indication that the poxvirus TK differs slightly from host cell TK in substrate specificity. This feature of the virus may be exploited to identify selective new poxvirus inhibitors. Indeed, Prichard and colleagues [8] later reported a series of 2′-deoxyuridine derivatives whose antiviral activity was highly dependent upon poxvirus TK.The antipoxvirus activities of certain compounds may be dependent upon the cell line in which the assay was conducted. For example, we found that BrdU was more potent against TK + than TK -vaccinia virus, but this effect was only seen in Vero monkey cells and A549